- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07493915
Precision Rehabilitation for Veterans With (HFpEF)
Precision Rehabilitation for Veterans With Heart Failure With Preserved Ejection Fraction (HFpEF)
This study is being completed because there is conflicting information regarding the value of monitored exercise in patients with heart failure with preserved ejection fraction (HFpEF). The purpose of this study is to collect baseline information necessary for researchers to pursue a larger study evaluating how monitored exercise performed during cardiac rehabilitation may improve heart health and the amount of oxygen delivered to the tissues during exercise. Researchers must first examine whether the facility is capable of supporting such a study and whether in a modest number of patients, there is no clear detrimental effect to exercise. Rather, there may be an important improvement that has been underestimated to date.
Participation will require a time commitment for performing exercise 3 times per week for 12 weeks in addition to having a small amount of blood drawn twice. There will also be a specialized form of a stress test (cardiopulmonary exercise test; "CPET") with ultrasound imaging of the heart (echocardiography) completed twice.
Study Overview
Status
Conditions
Detailed Description
Small studies have suggested that supervised exercise training improves cardiorespiratory fitness (CRF) in some patients with heart failure with preserved ejection fraction (HFpEF), but the response rate to exercise is broad, and the impact of exercise on quality of life and physical functioning at the Veteran level are incompletely understood. More recently, HFpEF patients randomized to moderate levels of exercise (moderate continuous training; MCT) increased VO2Peak, the quatitative measure of CRF) but not to the very aggressive level specified by the study. As such, the findings were considered statistically insignificant. To address the clinical question utilizing accepted targets, fill the scientific gaps, and advance the understanding of how monitored exercise improves both HFpEF severity and the lives of Veterans with HFpEF, an adequately powered study is required to assess the role of MCT for improving CRF, HF symptoms, QOL, physical functioning, and myocardial structure and function. Identifying patients at baseline likely to respond to MCT is the subject of the second aim and will be important for maximizing VA resources and delivering timely and effective care to veterans with HFpEF. The investigators plan to enroll 4 patients to provide preliminary and feasibility data to refine the protocol for the intended study, a request of the review committee who have favorably scored the MERIT proposal.
The long-term strategy is to improve exercise tolerance and functional capacity of HFpEF patients by favorably altering cardiac structure and function and the microRNA signature driving myocardial fibrosis. The investigators intend to conduct a larger study to test the central hypothesis that monitored exercise training improves CRF, HF symptoms, QOL, and functional status in veterans with HFpEF and that the expression pattern of miRs critical for regulating fibrosis (miR-,-21,-29,-133) can identify HFpEF patients responsive to exercise training when integrated into a comprehensive predictive tool incorporating clinical characteristics along with sensitive echocardiographic measures of LV diastolic function. This project will provide feasibility and preliminary data in 4 patients for the future study.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Kurt Barringhaus, MD, FACC, FSCAI
- Phone Number: 54106 803-776-4000
- Email: kurt.barringhaus@va.gov
Study Contact Backup
- Name: Amy Flowers
- Phone Number: 56006 80-776-4000
- Email: amy.flowers@va.gov
Study Locations
-
-
South Carolina
-
Columbia, South Carolina, United States, 29209
- Recruiting
- Columbia VA Health Care System
-
Contact:
- Kurt Barringhaus, MD, FACC, FSCAI
- Phone Number: 54106 803-776-4000
- Email: kurt.barringhaus@va.gov
-
Contact:
- Amy Flowers
- Phone Number: 56005 803-776-4000
- Email: amy.flowers@va.gov
-
Principal Investigator:
- Kurt Barringhaus, MD, FACC, FSCAI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- New York Heart Association Class II or III HF symptoms
- History of hypertension
- EF≥50%
- LVH confirmed by echocardiography, Cardiac CT, or Cardiac MR
Diastolic dysfunction which must include ≥2 of the following:
- Average E/e'>14
- Septal e'<7 cm/s or Lateral e' <10 cm/s
- TR velocity> 2.8 m/s
- LA computed volume index >34 mL/M2
- PCWP or LVEDP>15
- Ability to participate in an exercise program as determined by a research, cardiology, or primary care provider
Exclusion Criteria:
- Ejection Fraction < 50%
- Absence of LVH
- LV Dilation (LV end diastolic volume indexed to BSA > 75 ml/m2)
- Any Segmental wall motion abnormality
- Acute ST segment elevation myocardial infarction (STEMI)
- Significant valvular or other non-coronary heart disease
- Any non-cardiac disease or condition that could influence myocardial function (e.g., collagen-vascular disease, history of cardiotoxic cancer chemotherapy, amyloid)
- Anemia defined as Hgb < 11.0 g/dl in males, 10 g/dl in females
- Current accelerating angina, unstable angina, angina at rest, or NSTEMI within 3 months
- Chronic pulmonary disease requiring home oxygen or steroid therapy
- Significant non-CV organ disease: Chronic hepatic or renal disease (eGFR < 25 mL/min/1.73m2)
- Inability to provide informed consent
- Inability to perform exercise
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiorespiratory Fitness (CRF)
Time Frame: 12 Weeks
|
Change in cardiorespiratory fitness response (>10% increase in oxygen consumption on cardiopulmonary exercise testing).
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Kansas City Cardiomyopathy Questionnaire 12 total score
Time Frame: From patient enrollment to program completion at 12 weeks
|
Change in symptoms will be determined by assessing the difference in Kansas City Cardiomyopathy Questionnaire 12 total scores between baseline and exercise training program completion.
The total score ranges from 0 to 100 with higher scores indicating better health and symptom status.
|
From patient enrollment to program completion at 12 weeks
|
|
Change in 6 Minute Walk Distance (feet)
Time Frame: From enrollment to the end of the program at 12 Weeks
|
Change in physical functioning using the 6-minute walk test.
The change in 6 minute walking distance is expressed as an absolute value with longer distances indicating better health and physical functioning.
|
From enrollment to the end of the program at 12 Weeks
|
|
Exercise capacity
Time Frame: From patient enrollment to program completion at 12 weeks
|
Change in exercise capacity in metabolic equivalents
|
From patient enrollment to program completion at 12 weeks
|
|
Myocardial stiffness
Time Frame: From patient enrollment to program completion at 12 weeks
|
Change in LV myocardial and chamber stiffness by tissue doppler echocardiography
|
From patient enrollment to program completion at 12 weeks
|
|
Plasma MicroRNA
Time Frame: From patient enrollment to program completion at 12 weeks
|
Change in plasma levels of miRs
|
From patient enrollment to program completion at 12 weeks
|
|
Physical Functioning
Time Frame: From patient enrollment to program completion at 12 weeks
|
Change in physical functioning will be determined by assessing the difference in the summed score of questions 3-12 of the Short Form Survey (SF-36).
The summed score ranges from 10-30 with higher scores indicating higher levels of physical functioning.
|
From patient enrollment to program completion at 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kurt Barringhaus, MD, FACC, FSCAI, William Jennings Bryan Dorn VA Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1699596
- Facility Funds (Other Identifier: William Jennings Bryan DORN)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Umeå UniversityRegion NorrbottenNot yet recruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureSweden
-
University of Health Sciences LahoreRecruitingAcute Decompensated Heart Failure | Heart Failure, Diastolic | Heart Failure, SystolicPakistan
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Lakeland Regional Health Systems, Inc.RecruitingHeart Failure | Heart Failure Acute | Acute Heart Failure (AHF) | Heart Failure - NYHA II - IVUnited States
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Eli Lilly and CompanyNot yet recruitingHeart Failure | Heart Failure, Diastolic | Heart Failure, SystolicUnited States, Japan
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States